Pegadricase

The 2025 Drugs to Watch™ report by Clarivate highlights 11 transformative therapies in obesity, oncology, gene therapy, and more, expected to achieve blockbuster status or revolutionize treatment by 2030. It emphasizes advancements in AI, machine learning, and regulatory frameworks, showcasing the life sciences sector's resilience and innovation in improving global patient care.

SEL-212, a monthly two-component infusion therapy, improved patient-reported outcomes (PROs) in refractory gout patients after 3 doses, with further improvement after 6 doses, as shown in Phase 3 trials presented at ACR Convergence 2024.

Morningstar lowers Swedish Orphan Biovitrum's Uncertainty Rating to Medium from High due to diversified revenue via acquisitions in hematology and immunology. Hemophilia drug revenue concentration has declined from 60% in 2018 to 40% in 2023, expected to drop to mid-30s. New products like Altuviiio, SEL-212, and Vonjo will drive future growth. Fair value estimate remains SEK 343 with a narrow moat rating; shares appear undervalued.